Gary Buchschacher
Hematology & Oncology · Los Angeles, CANPI 1730250705
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $4,367 of the $7,069 with a category attached, or 61.8%. 3 manufacturers reported payments, led by Roche Products Limited at 58.7% of the total.
Across 19 payments — averaging $372.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Products Limited$4K
- F. Hoffmann-la Roche AG$2K
- Astrazeneca UK Limited$1K
Across 577 payments — averaging $13,697 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$4.1M
- AstraZeneca$2.3M
- GSK$478K
- Merck$398K
- Seagen Inc.$293K
- Pfizer$207K
- plus $165K from 5 others
What the payments were for
- Speaking & faculty fees$1,84226%
- Travel & lodging$4,36762%
- Food & beverage$85912%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche Products Limited | 8 | $4,147 |
| F. Hoffmann-la Roche AG | 3 | $1,842 |
| Astrazeneca UK Limited | 8 | $1,079 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TECENTRIQ$4,082
- Avastin$2,838
- Non-Covered Product$1,842
How this compares
$7,069 in reported general payments places this provider in the 60th percentile of 1,363 hematology & oncology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 34 | $525,734 |
| XtandiEnzalutamide | 15 | $183,432 |
| Abiraterone Acetate | 44 | $7,130 |
| Imatinib Mesylate | 11 | $1,575 |
| Anastrozole | 50 | $1,395 |
| Tamoxifen Citrate | 15 | $500 |
| Alendronate Sodium | 25 | $245 |
| Prednisone | 23 | $237 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Los Angeles
- Dennis SlamonLos Angeles$3.1M
- George YaghmourLos Angeles$1.9M
- Kevin KellyLos Angeles$894K
- Raghuveer RanganathanLos Angeles$609K
- Matthew RettigLos Angeles$442K
- David BerzLos Angeles$420K
- Gottfried KonecnyLos Angeles$402K
- Antoni RibasLos Angeles$315K
- Edward GaronLos Angeles$301K
- Rahul NaikLos Angeles$297K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.